866-997-4948(US-Canada Toll Free)

Solid Tumor Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Oncology

No. of Pages : 584 Pages


Global Markets Directs, \'Solid Tumor Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Solid Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Solid Tumor. 

Solid Tumor Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Solid Tumor.
  • A review of the Solid Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Solid Tumor pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Solid Tumor.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Solid Tumor pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 9
List of Figures 21
Introduction 23
Global Markets Direct Report Coverage 23
Solid Tumor Overview 24
Therapeutics Development 25
An Overview of Pipeline Products for Solid Tumor 25
Solid Tumor Therapeutics under Development by Companies 27
Solid Tumor Therapeutics under Investigation by Universities/Institutes 52
Late Stage Products 64
Comparative Analysis 64
Mid Clinical Stage Products 65
Comparative Analysis 65
Early Clinical Stage Products 66
Comparative Analysis 66
Discovery and Pre-Clinical Stage Products 67
Comparative Analysis 67
Solid Tumor Therapeutics Products under Development by Companies 68
Solid Tumor Therapeutics Products under Investigation by Universities/Institutes 129
Companies Involved in Solid Tumor Therapeutics Development 166
Bristol-Myers Squibb Company 166
Genzyme Corporation 167
Baxter International Inc. 168
Johnson & Johnson 169
Boehringer Ingelheim GmbH 170
F. Hoffmann-La Roche Ltd. 171
Kyowa Hakko Kirin Co., Ltd. 172
Abbott Laboratories 173
Biogen Idec Inc. 174
Amgen Inc. 175
Sanofi-Aventis 176
Adherex Technologies Inc. 178
AstraZeneca PLC 179
Eli Lilly and Company 181
GlaxoSmithKline plc 182
Seattle Genetics, Inc. 184
Tekmira Pharmaceuticals Corp. 185
Genentech, Inc. 186
Nektar Therapeutics 187
Inovio Biomedical Corporation 188
MedImmune LLC 189
Debiopharm Group 324
Chroma Therapeutics Ltd. 325
Colby Pharmaceutical Company 326
Affimed Therapeutics AG 327
Wilex AG 328
Chipscreen Biosciences Ltd 329
INSYS Therapeutics, Inc. 330
Biotecnol SA 331
Ambit Biosciences Corporation 332
Actinium Pharmaceuticals, Inc. 333
Philogen S.p.A. 334
Acceleron Pharma, Inc. 335
Pieris AG 336
Nerviano Medical Sciences S.r.l. 337
BioMAS Ltd. 338
Glycotope GmbH 339
Neovacs SA 340
Hutchison MediPharma Limited 341
ERYtech Pharma 342
LiPlasome Pharma A/S 343
Apogenix GmbH 344
BioNumerik Pharmaceuticals, Inc. 345
Aegera Therapeutics Inc. 346
Altor BioScience Corporation 347
Provecs Medical GmbH 348
EnGeneIC Ltd 349
AgrenVec, S.L. 350
Angiogene Pharmaceuticals Ltd. 351
GenSpera, Inc. 352
Ascenta Therapeutics, Inc. 353
Phoenix Biotechnology, Inc. 354
Allozyne, Inc. 355
Coronado Biosciences, Inc. 356
Cerulean Pharma, Inc. 357
MacroGenics, Inc. 358
Pervasis Therapeutics, Inc. 359
Arno Therapeutics, Inc. 360
ACT Biotech, Inc. 361
OncoMed Pharmaceuticals, Inc. 362
TetraLogic Pharmaceuticals 363
Boston Biomedical, Inc. 364
Five Prime Therapeutics, Inc. 365
PanaGin Pharmaceuticals Inc. 366
Vaccinex, Inc. 367
Azaya Therapeutics, Inc. 368
Semafore Pharmaceuticals, Inc. 369
CanBas Co., Ltd. 370
Merrimack Pharmaceuticals, Inc. 371
PTC Therapeutics, Inc. 372
RESprotect GmbH 373
Deciphera Pharmaceuticals, LLC 374
MSM Protein Technologies, Inc. 375
Novation Pharmaceuticals, Inc. 376
ProNAi Therapeutics, Inc. 377
Mersana Therapeutics, Inc. 378
Vascular Biogenics Ltd. 379
Jennerex Biotherapeutics, Inc. 380
Stemline Therapeutics, Inc. 381
Axelar AB 382
Endocyte, Inc. 383
Proacta, Inc. 384
Cornerstone Pharmaceuticals, Inc. 385
Omnitura Therapeutics Inc. 386
Advenchen Laboratories, LLC 387
AndroScience Corporation 388
Onconova Therapeutics, Inc 389
MolMed S.p.A. 390
Pharminox Limited 391
Syndax Pharmaceuticals, Inc. 392
NOXXON Pharma AG 393
NovaLead Pharma Pvt. Ltd. 394
Esperance Pharmaceuticals, Inc. 395
Mirna Therapeutics, Inc. 396
Transtech Pharma, Inc. 397
Welichem Biotech Inc. 398
Globeimmune, Inc. 399
APEIRON Biologics AG 400
Immunocore Limited. 401
BIND Biosciences, Inc. 402
NewLink Genetics Corporation 403
InteRNA Technologies B.V. 404
Tragara Pharmaceuticals, Inc. 405
4-Antibody AG 406
Taiwan Liposome Company 407
Drais Pharmaceuticals, Inc. 408
Cellceutix Corporation 409
PharmaMar, S.A. 410
Quintessence Biosciences, Inc. 411
Bellicum Pharmaceuticals, Inc. 412
VentiRx Pharmaceuticals, Inc. 413
AmpliMed Corporation 414
arGEN-X BV 415
Kinex Pharmaceuticals, LLC 416
SynDevRx, Inc. 417
Tigris Pharmaceuticals, Inc. 418
to-BBB technologies BV 419
Cylene Pharmaceuticals, Inc. 420
Genelux Corporation 421
Nereus Pharmaceuticals, Inc. 422
Viventia Biotechnologies Inc. 423
AVEO Pharmaceuticals, Inc. 424
Lytix Biopharma AS 425
Kringle Pharma, Inc. 426
TRACON Pharmaceuticals, Inc. 427
CytImmune Sciences, Inc. 428
KAHR medical Ltd. 429
Adamed Sp. z o.o. 430
Centocor Ortho Biotech, Inc. 431
Advanced Cancer Therapeutics 432
Elara Pharmaceuticals GmbH 433
Clovis Oncology, Inc. 434
EOS S.p.A. 435
Amplimmune, Inc. 436
Pathway Therapeutics Limited 437
PNP Therapeutics, Inc. 438
Cancer Therapeutics CRC Pty Ltd 439
Zenyaku Kogyo Co., Ltd. 440
Interprotein Corporation 441
Targa Therapeutics Corp. 442
BioProspecting NB, Inc. 443
ImmunoFrontier, Inc. 444
Jiangsu Kanion Pharmaceutical Co., Ltd. 445
Kyowa Hakko Kirin Pharma, Inc. 446
Almac Discovery Ltd. 447
NuCana BioMed Limited 448
Mayo Clinic 449
Medical Enzymes AG 450
Sentinel Oncology Limited 451
Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 452
PBL Therapeutics 453
Errant Gene Therapeutics, LLC 454
Mebiopharm Co., Ltd. 455
Polaris Group 456
IkerChem S.L. 457
Agennix AG 458
ImQuest Life Sciences 459
Gradalis Inc. 460
Solid Tumor Therapeutics Assessment 461
Assessment by Monotherapy Products 461
Assessment by Combination Products 462
Assessment by Route of Administration 463
Assessment by Molecule Type 465
Drug Profiles 467
ramucirumab - Drug Profile 467
girentuximab - Drug Profile 469
Cyclophosphamide + Total Body Radiation - Drug Profile 471
Carboplatin + Thiotepa + Cyclophosphamide + Allogeneic Stem Cell Transplantation - Drug Profile 472
memantine - Drug Profile 473
levofloxacin - Drug Profile 474
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile 475
Busulfan + Cyclophosphamide + Autologous Stem Cell Transplantation - Drug Profile 476
Dexamethason + Metoclopramide - Drug Profile 477
Dexamethasone + Dronabinol + Palonosetron hydrochloride - Drug Profile 478
Dexamethasone + Gabapentin - Drug Profile 480
Dexamethasone + Granisetron - Drug Profile 482
Dexamethasone + Granisetron Hydrochloride + Metoclopramide Hydrochloride - Drug Profile 483
SAR-240550 + Liposomal Doxorubicin + Carboplatin - Drug Profile 485
Solid Tumor Therapeutics Drug Profile Updates 487
Solid Tumor Therapeutics Discontinued Products 489
Solid Tumor Therapeutics - Dormant Products 505
Solid Tumor Product Development Milestones 575
Featured News & Press Releases 575

Appendix 582
Methodology 582
Coverage 582
Secondary Research 582
Primary Research 582
Expert Panel Validation 582
Contact Us 583
Disclaimer 583

List of Table


Number of Products Under Development for Solid Tumor, H2 2012 26
Products under Development for Solid Tumor Comparative Analysis, H2 2012 27
Number of Products under Development by Companies, H2 2012 29
Number of Products under Development by Companies, H2 2012 (Contd..1) 30
Number of Products under Development by Companies, H2 2012 (Contd..2) 31
Number of Products under Development by Companies, H2 2012 (Contd..3) 32
Number of Products under Development by Companies, H2 2012 (Contd..4) 33
Number of Products under Development by Companies, H2 2012 (Contd..5) 34
Number of Products under Development by Companies, H2 2012 (Contd..6) 35
Number of Products under Development by Companies, H2 2012 (Contd..7) 36
Number of Products under Development by Companies, H2 2012 (Contd..8) 37
Number of Products under Development by Companies, H2 2012 (Contd..9) 38
Number of Products under Development by Companies, H2 2012 (Contd..10) 39
Number of Products under Development by Companies, H2 2012 (Contd..11) 40
Number of Products under Development by Companies, H2 2012 (Contd..12) 41
Number of Products under Development by Companies, H2 2012 (Contd..13) 42
Number of Products under Development by Companies, H2 2012 (Contd..14) 43
Number of Products under Development by Companies, H2 2012 (Contd..15) 44
Number of Products under Development by Companies, H2 2012 (Contd..16) 45
Number of Products under Development by Companies, H2 2012 (Contd..17) 46
Number of Products under Development by Companies, H2 2012 (Contd..18) 47
Number of Products under Development by Companies, H2 2012 (Contd..19) 48
Number of Products under Development by Companies, H2 2012 (Contd..20) 49
Number of Products under Development by Companies, H2 2012 (Contd..21) 50
Number of Products under Development by Companies, H2 2012 (Contd..22) 51
Number of Products under Development by Companies, H2 2012 (Contd..23) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 56
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 57
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 58
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 59
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 60
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 61
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 62
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 63
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 64
Comparative Analysis by Late Stage Development, H2 2012 65
Comparative Analysis by Mid Clinical Stage Development, H2 2012 66
Comparative Analysis by Early Clinical Stage Development, H2 2012 67
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 68
Products under Development by Companies, H2 2012 69
Products under Development by Companies, H2 2012 (Contd..1) 70
Products under Development by Companies, H2 2012 (Contd..2) 71
Products under Development by Companies, H2 2012 (Contd..3) 72
Products under Development by Companies, H2 2012 (Contd..4) 73
Products under Development by Companies, H2 2012 (Contd..5) 74
Products under Development by Companies, H2 2012 (Contd..6) 75
Products under Development by Companies, H2 2012 (Contd..7) 76
Products under Development by Companies, H2 2012 (Contd..8) 77
Products under Development by Companies, H2 2012 (Contd..9) 78
Products under Development by Companies, H2 2012 (Contd..10) 79
Products under Development by Companies, H2 2012 (Contd..11) 80
Products under Development by Companies, H2 2012 (Contd..12) 81
Products under Development by Companies, H2 2012 (Contd..13) 82
Products under Development by Companies, H2 2012 (Contd..14) 83
Products under Development by Companies, H2 2012 (Contd..15) 84
Products under Development by Companies, H2 2012 (Contd..16) 85
Products under Development by Companies, H2 2012 (Contd..17) 86
Products under Development by Companies, H2 2012 (Contd..18) 87
Products under Development by Companies, H2 2012 (Contd..19) 88
Products under Development by Companies, H2 2012 (Contd..20) 89
Products under Development by Companies, H2 2012 (Contd..21) 90
Products under Development by Companies, H2 2012 (Contd..22) 91
Products under Development by Companies, H2 2012 (Contd..23) 92
Products under Development by Companies, H2 2012 (Contd..24) 93
Products under Development by Companies, H2 2012 (Contd..25) 94
Products under Development by Companies, H2 2012 (Contd..26) 95
Products under Development by Companies, H2 2012 (Contd..27) 96
Products under Development by Companies, H2 2012 (Contd..28) 97
Products under Development by Companies, H2 2012 (Contd..29) 98
Products under Development by Companies, H2 2012 (Contd..30) 99
Products under Development by Companies, H2 2012 (Contd..31) 100
Products under Development by Companies, H2 2012 (Contd..32) 101
Products under Development by Companies, H2 2012 (Contd..33) 102
Products under Development by Companies, H2 2012 (Contd..34) 103
Products under Development by Companies, H2 2012 (Contd..35) 104
Products under Development by Companies, H2 2012 (Contd..36) 105
Products under Development by Companies, H2 2012 (Contd..37) 106
Products under Development by Companies, H2 2012 (Contd..38) 107
Products under Development by Companies, H2 2012 (Contd..39) 108
Products under Development by Companies, H2 2012 (Contd..40) 109
Products under Development by Companies, H2 2012 (Contd..41) 110
Products under Development by Companies, H2 2012 (Contd..42) 111
Products under Development by Companies, H2 2012 (Contd..43) 112
Products under Development by Companies, H2 2012 (Contd..44) 113
Products under Development by Companies, H2 2012 (Contd..45) 114
Products under Development by Companies, H2 2012 (Contd..46) 115
Products under Development by Companies, H2 2012 (Contd..47) 116
Products under Development by Companies, H2 2012 (Contd..48) 117
Products under Development by Companies, H2 2012 (Contd..49) 118
Products under Development by Companies, H2 2012 (Contd..50) 119
Products under Development by Companies, H2 2012 (Contd..51) 120
Products under Development by Companies, H2 2012 (Contd..52) 121
Products under Development by Companies, H2 2012 (Contd..53) 122
Products under Development by Companies, H2 2012 (Contd..54) 123
Products under Development by Companies, H2 2012 (Contd..55) 124
Products under Development by Companies, H2 2012 (Contd..56) 125
Products under Development by Companies, H2 2012 (Contd..57) 126
Products under Development by Companies, H2 2012 (Contd..58) 127
Products under Development by Companies, H2 2012 (Contd..59) 128
Products under Development by Companies, H2 2012 (Contd..60) 129
Products under Investigation by Universities/Institutes, H2 2012 130
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 131
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 132
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 133
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 134
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 135
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 136
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 137
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 138
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 139
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 140
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 141
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 142
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 143
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 144
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 145
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 146
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 147
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 148
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 149
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 150

List of Chart


Number of Products under Development for Solid Tumor, H2 2012 26
Products under Development for Solid Tumor Comparative Analysis, H2 2012 27
Products under Development by Companies, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 53
Late Stage Products, H2 2012 65
Mid Clinical Stage Products, H2 2012 66
Early Clinical Stage Products, H2 2012 67
Discovery and Pre-Clinical Stage Products, H2 2012 68
Assessment by Monotherapy Products, H2 2012 462
Assessment by Combination Products, H2 2012 463
Assessment by Route of Administration, H2 2012 464
Assessment by Stage and Route of Administration, H2 2012 465
Assessment by Molecule Type, H2 2012 466
Assessment by Stage and Molecule Type, H2 2012 467

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *